1
|
Corsini CA, Martins PFDS, Filgueiras PS, Lourenço AJ, Lima AEDS, Gomes SVC, Jeremias WDJ, Alves PA, Fernandes GDR, Castro LLME, de Carvalho AT, Azevedo ACC, Curimbaba CDAL, Lorencini DA, Junior EM, da Silva VM, Cervi MC, Borges MDC, Nogueira ML, Campos GRF, Correa PRL, Carvalho TML, dos Reis JGAC, Reis EVDS, Castilho LDR, de Lima PR, do Nascimento JPR, de Oliveira JG, Filho OAM, Grenfell RFQE. Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up. Res Sq 2024:rs.3.rs-3931021. [PMID: 38464059 PMCID: PMC10925469 DOI: 10.21203/rs.3.rs-3931021/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/12/2024]
Abstract
Introduction Vaccines are essential for the prevention and control of several diseases, indeed, monitoring the immune response generated by vaccines is crucial. The immune response generated by vaccination against SARS-CoV-2 in children and adolescents is not well defined regarding to the intensity and medium to long-term duration of a protective immune response, which may point out the need of booster doses and might support the decisions in public health. Objective The study aims to evaluate the immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in a two-dose primary protocol in children and adolescent aging from 3 to 17 years old in Brazil. Methods Participants were invited to participate in the research at two public healthcare centers located in Serrana (São Paulo) and Belo Horizonte (Minas Gerais), Brazil. Participants underwent medical interviews to gather their medical history, including COVID-19 history and medical records. Physical exams were conducted, including weight, blood pressure, temperature, and pulse rate measurements. Blood samples were obtained from the participants before vaccination, 1 month after the first dose, and 1, 3, and 6 months after the second dose and were followed by a virtual platform for monitoring post-vaccination reactions and symptoms of COVID-19. SARS-CoV-2 genome from Swab samples of COVID-19 positive individuals were sequenced by NGS. Total antibodies were measured by ELISA and neutralizing antibodies to B.1 lineage and Omicron variant (BA.1) quantified by PRNT and VNT. The cellular immune response was evaluated by flow cytometry by the quantification of systemic soluble immune mediators. Results The follow-up of 640 participants showed that the CoronaVac vaccine (Sinovac/Butantan Institute) was able to significantly induce the production of total IgG antibodies to SARS-CoV-2 and the production of neutralizing antibodies to B.1 lineage and Omicron variant. In addition, a robust cellular immune response was observed with wide release of pro-inflammatory and regulatory mediators in the early post-immunization moments. Adverse events recorded so far have been mild and transient except for seven serious adverse events reported on VigiMed. Conclusions The results indicate a robust and sustained immune response induced by the CoronaVac vaccine in children and adolescents up to six months, providing evidences to support the safety and immunogenicity of this effective immunizer.
Collapse
Affiliation(s)
- Camila Amormino Corsini
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | | | - Priscilla Soares Filgueiras
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Adelina Júnia Lourenço
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Ana Esther de Souza Lima
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Sarah Vieira Contin Gomes
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Wander de Jesus Jeremias
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
- Department of Pharmacy, Federal University of Ouro Preto (UFOP). 27, Nove, Bauxita, Ouro Preto, Brazil. 35400-000
| | - Pedro Augusto Alves
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Gabriel da Rocha Fernandes
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | | | - Andrea Teixeira de Carvalho
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Ana Carolina Campi Azevedo
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | | | | | | | | | - Maria Célia Cervi
- Faculty of Medicine, University of São Paulo (USP). 455 Doutor Arnaldo Avenue, São Paulo, São Paulo, Brazil. 01246-903
| | - Marcos de Carvalho Borges
- Faculty of Medicine, University of São Paulo (USP). 455 Doutor Arnaldo Avenue, São Paulo, São Paulo, Brazil. 01246-903
- Serrana Clinical Research Center. 438, 13 de Maio, Centro, Serrana, São Paulo, Brazil. 14150-000
| | - Maurício Lacerda Nogueira
- Faculty of Medicine of São José do Rio Preto (FAMERP). 5416 Brigadeiro Faria Lima Avenue, São José do Rio Preto, São Paulo, Brazil. 15090-000
- Hospital de Base, 5544 Brigadeiro Faria Lima Avenue, São José do Rio Preto, São Paulo State, Brazil. 15090-000
- Department of Pathology, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, USA. 77555
| | | | - Paulo Roberto Lopes Correa
- Belo Horizonte Municipal Health Department (SMS), 2336 Afonso Pena Avenue, Belo Horizonte, Brazil. 30130-012
| | | | | | - Erik Vinícius de Sousa Reis
- Federal University of Minas Gerais (UFMG). 6627 Presidente Antônio Carlos Avenue, Belo Horizonte, Minas Gerais, Brazil. 31270-901
| | - Leda dos Reis Castilho
- Cell Culture Engineering Laboratory (COPPE), Federal University of Rio de Janeiro (UFRJ). 550 Pedro Calmon Avenue, Rio de Janeiro, Rio de Janeiro, Brazil. 21941-598
| | | | | | | | - Olindo Assis Martins Filho
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
| | - Rafaella Fortini Queiroz e Grenfell
- Oswaldo Cruz Foundation (FIOCRUZ). 1715 Augusto de Lima Avenue, Belo Horizonte, Minas Gerais, Brazil. 30190-002
- Federal University of Minas Gerais (UFMG). 6627 Presidente Antônio Carlos Avenue, Belo Horizonte, Minas Gerais, Brazil. 31270-901
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia (UGA). 501 DW Brooks Drive, Athens, Georgia, USA. 30602-7387
| | | |
Collapse
|